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1. INTRODUCTION {#cam42397-sec-0005}
===============

Immune checkpoint inhibitors (CPIs) have revolutionized cancer therapy over the past decade.[1](#cam42397-bib-0001){ref-type="ref"}, [2](#cam42397-bib-0002){ref-type="ref"} CPIs are clinically associated with durable responses in a wide range of cancers, including those of any origin with microsatellite instability or mismatch‐repair deficiencies, and the use of CPIs is rapidly growing.[3](#cam42397-bib-0003){ref-type="ref"}, [4](#cam42397-bib-0004){ref-type="ref"}, [5](#cam42397-bib-0005){ref-type="ref"}, [6](#cam42397-bib-0006){ref-type="ref"}, [7](#cam42397-bib-0007){ref-type="ref"} This novel class of agents enhances adaptive immune responses to cancer through inhibition of major T‐lymphocyte coinhibitory pathways that otherwise block "immune escape" mechanisms.[2](#cam42397-bib-0002){ref-type="ref"}

Autoimmune‐like syndromes, termed immune‐related adverse events (irAEs), are becoming increasingly common as more patients are treated with CPIs.[1](#cam42397-bib-0001){ref-type="ref"}, [7](#cam42397-bib-0007){ref-type="ref"}, [8](#cam42397-bib-0008){ref-type="ref"}, [9](#cam42397-bib-0009){ref-type="ref"}, [10](#cam42397-bib-0010){ref-type="ref"}, [11](#cam42397-bib-0011){ref-type="ref"}, [12](#cam42397-bib-0012){ref-type="ref"} Though any organ system can be affected, irAEs typically involve the skin, gastrointestinal tract, and lungs.[13](#cam42397-bib-0013){ref-type="ref"} The severity and spectrum of irAEs are related to the specific pathway targeted, with inhibition of cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4) generally having more frequent and more severe irAEs compared to inhibitors of programmed cell death‐1 (PD‐1) or its ligand (PD‐L1).[1](#cam42397-bib-0001){ref-type="ref"} Combination CPI therapy leads to more significant irAEs than either therapy alone.[12](#cam42397-bib-0012){ref-type="ref"}

Gastroenterocolitis (GEC) is among the most common and severe irAEs associated with CPIs.[1](#cam42397-bib-0001){ref-type="ref"}, [12](#cam42397-bib-0012){ref-type="ref"}, [14](#cam42397-bib-0014){ref-type="ref"}, [15](#cam42397-bib-0015){ref-type="ref"} Depending on the targeted pathway, 20%‐50% of patients receiving commercially available CPI monotherapy develop some form of CPI‐related GEC, and 2%‐10% develop severe disease; rarely, bowel perforations can occur.[6](#cam42397-bib-0006){ref-type="ref"}, [8](#cam42397-bib-0008){ref-type="ref"}, [16](#cam42397-bib-0016){ref-type="ref"}, [17](#cam42397-bib-0017){ref-type="ref"}, [18](#cam42397-bib-0018){ref-type="ref"} Combination CPI therapy results in 46%‐51% of the exposed patients developing CPI‐related GEC, with 8%‐18% developing a severe form.[9](#cam42397-bib-0009){ref-type="ref"} CPI‐related GEC is accompanied by significant morbidity and substantial cost.[19](#cam42397-bib-0019){ref-type="ref"} First‐line treatment consists of immunosuppression with high‐dose corticosteroids (1‐2 mg/kg daily of prednisone or equivalent).[7](#cam42397-bib-0007){ref-type="ref"}, [20](#cam42397-bib-0020){ref-type="ref"} Tumor necrosis factor alpha (TNFα) inhibitors such as infliximab are standard second‐line treatment.[7](#cam42397-bib-0007){ref-type="ref"} Clinically, one of the most important factors complicating management of CPI‐related GEC is whether a patient responds to first‐line corticosteroids, and thus predictors of the need for second‐line immune suppression are of considerable clinical interest.

Severe CPI‐related GEC requiring hospitalization often necessitates acute intervention and forces oncologists to make difficult choices regarding further immunotherapy, including discontinuation of treatment. There are few published studies, however, describing a consolidated patient cohort hospitalized for the condition. We thus aimed to clinically characterize CPI‐related GEC requiring hospitalization in a retrospective cohort study, focusing on clinical factors that are associated with the requirement for secondary immune suppression.

2. METHODS {#cam42397-sec-0006}
==========

2.1. Ethics {#cam42397-sec-0007}
-----------

This study was approved by the Partners Human Research Committee, the Institutional Review Board of the Massachusetts General Hospital (MGH).

2.2. Patients {#cam42397-sec-0008}
-------------

We identified all patients ≥18 years of age with stage III/IV melanoma hospitalized at Massachusetts General Hospital for expert‐confirmed CPI‐related GEC from February 05, 2011 to December 13, 2016; patients were followed for further admissions until December 31, 2017 (MGH Research Patient Data Registry). CPI‐related GEC was defined as clinical and/or histopathologic evidence of gastrointestinal inflammation best explained by prior CPI exposure. Diagnoses were confirmed by two reviewers with expertise in CPI complications (Figure [1](#cam42397-fig-0001){ref-type="fig"}). The cohort was divided into two comparison cohorts based on the use of corticosteroids alone, or combination with second‐line immune suppression for the treatment of CPI‐related GEC. The decision to use second‐line immune suppression was made by the treating medical team, and did not follow an explicit protocol; in general, the decision to start secondary immune suppression was made based on (a) lack of sufficient initial response to corticosteroids; and (b) recurrence of colitis symptoms upon corticosteroid taper. Treatment decisions were reviewed by two people with expertise in CPI complications and the use of secondary immune suppression was confirmed.

![Process diagram depicting the generation of the patient cohort upon which descriptive and analytic statistics were performed. Patients were excluded at the initial screening for the following reasons: under 18 years of age; admitted for primary hospital problems unlikely to be secondary to irAEs. Patients were excluded at the second screening for the following reasons: complete absence of diarrhea, nausea/vomiting, or abdominal pain; otherwise admitted for primary hospital problems definitively not secondary to CPI‐related GEC. Patients were excluded at the audits stage by expert opinion after careful review of the electronic medical record. CPI, checkpoint inhibitor; GEC, gastroenterocolitis; irAEs, immune‐related adverse events](CAM4-8-4986-g001){#cam42397-fig-0001}

2.3. Data collection {#cam42397-sec-0009}
--------------------

We extracted clinical, laboratory, radiographic, and endoscopic data from electronic medical records (Table [S1](#cam42397-sup-0003){ref-type="supplementary-material"}). The National Cancer Institute\'s Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 was used for adverse event classification. Two independent database audits confirmed high accuracy.

2.4. Endpoints {#cam42397-sec-0010}
--------------

Primary endpoints were progression‐free survival (PFS) and overall survival (OS). Secondary endpoints were length of stay (LOS), rate of readmission, and time to GEC resolution (grade 1 symptoms or better).

2.5. Statistical analysis {#cam42397-sec-0011}
-------------------------

Patients were grouped in three primary ways for analysis: by CTCAE; by whether or not they received second‐line immunosuppression; and by whether they received corticosteroids earlier or later in their disease course. Descriptive statistics were displayed using Microsoft Excel 2016 (Microsoft Corporation, Redmond, Washington, DC). Statistical analysis was performed using SAS Studio (version 9.4M6, SAS Institute, Cary, NC). Data are expressed as "mean ± standard deviation," "mean ± standard error," or "median (range)" where appropriate. P‐values are two‐sided, with α = 0.05.

The chi‐squared test or Fisher\'s exact test and the ANOVA method or the Student\'s *t* test were employed where appropriate. Survival curves were generated using Kaplan‐Meier analysis. Log‐rank and Wilcoxon testing are reported where appropriate. Survival was measured from CPI exposure date to date of death, date of transition to hospice, or censored date. Date of death or transition to hospice was determined by electronic medical record review. Date of cancer progression was defined as the date imaging was performed showing progressive disease. Median follow‐up time was 28.0 months. Twenty‐eight patients transitioned to hospice care and/or died during the study interval. With a sample size of 30 in each subgroup, a follow‐up time of 60 months, and a median PFS of 10.5 months in those who did not receive second‐line immunosuppression and 30.5 months in those who did receive second‐line immunosuppression, we calculated that our study has over 80% power to detect a survival difference between populations using a two‐sided log‐rank test at a significance level of 0.05.

3. RESULTS {#cam42397-sec-0012}
==========

3.1. Characteristics and typical hospital course of severe CPI‐related GEC {#cam42397-sec-0013}
--------------------------------------------------------------------------

Baseline characteristics are summarized in Table [1](#cam42397-tbl-0001){ref-type="table"}. Sixty patients with advanced melanoma, totaling 88 admissions, were hospitalized for CPI‐related GEC from June 1, 2011 to December 31, 2017. Average age on admission was 65 years; 38/60 (63%) patients were male and 52/60 (86.7%) had stage IV melanoma. Metastasis to the liver and the gastrointestinal tract were 35.0% (21/60, 35.0%) and 21.7% (13/60, 21.7%), respectively. Median Eastern Cooperative Oncology Group (ECOG) performance status was 0 at the time of CPI initiation.

###### 

Characteristics of the patients at baseline

                                                                       Overall         No use of second‐line immunosuppression   Use of second line immunosuppression   *P*‐value
  -------------------------------------------------------------------- --------------- ----------------------------------------- -------------------------------------- ----------------------------------------------
  Number of patients                                                   60              30/60 (50.0%)                             30/60 (50.0%)                          1.000
  Number of admissions                                                 88              35/88 (39.8%)                             53/88 (60.3%)                          0.288
  Age in years (mean ± SD)                                             65.1 ± 12.2     67.9 ± 12.3                               62.4 ± 11.6                            0.080
  Sex (M:F)                                                            38:22           18:12                                     20:10                                  0.592
  ICI regimen                                                                                                                                                           
  Ipilimumab                                                           28/60 (46.7%)   9/30 (30.0%)                              19/30 (63.3%)                          0.010[a](#cam42397-note-0004){ref-type="fn"}
  Pembrolizumab                                                        7/60 (11.7%)    6/30 (20.0%)                              1/30 (3.3%)                            0.103
  Nivolumab                                                            1/60 (1.7%)     1/30 (3.3%)                               0/30 (0.0%)                            1.000
  Combination                                                          24/60 (40.0%)   14/30 (46.7%)                             10/30 (33.3%)                          0.292
  Other                                                                2/60 (3.3%)     1/30 (3.3%)                               1/30 (3.3%)                            1.000
  Tumor stage                                                                                                                                                           
  II                                                                   1/60 (1.7%)     1/30 (3.3%)                               0/30 (0.0%)                            0.011[a](#cam42397-note-0004){ref-type="fn"}
  III                                                                  7/60 (11.7%)    0/30 (0.0%)                               7/30 (23.3%)                           
  IV                                                                   52/60 (86.7%)   29/30 (96.7%)                             23/30 (76.7%)                          
  Prior therapies                                                                                                                                                       
  Median number of prior therapies (IQR)                               2 (1‐3)         1 (1‐2)                                   2 (1‐3)                                0.076
  Resection                                                            46/60 (76.7%)   22/30 (73.3%)                             24/30 (80.0%)                          0.542
  Radiation                                                            25/60 (41.7%)   11/30 (36.7%)                             14/30 (46.7%)                          0.432
  Pegylated interferon                                                 12/60 (20.0%)   4/30 (13.3%)                              8/30 (26.7%)                           0.197
  Targeted inhibitor                                                   15/60 (25.0%)   7/30 (23.3%)                              8/30 (26.7%)                           0.766
  Chemotherapy                                                         2/60 (3.3%)     2/30 (6.7%)                               0/30 (0.0%)                            0.492
  CPI                                                                  8/60 (13.3%)    3/30 (10.0%)                              5/30 (16.7%)                           0.706
  Gastrointestinal metastases                                                                                                                                           
  Liver                                                                21/60 (35.0%)   11/30 (36.7%)                             10/30 (33.3%)                          0.787
  Other                                                                13/60 (21.7%)   10/30 (33.3%)                             3/30 (10.0%)                           0.028[a](#cam42397-note-0004){ref-type="fn"}
  Median ECOG performance status at initial CPI administration (IQR)   0 (0‐1)         0 (0‐1)                                   1 (0‐1)                                0.358

Selected typical characteristics of patients with CPI‐related GEC requiring admission. Univariate analysis displayed. The *P*‐value was calculated by ANOVA for numerical covariates and chi‐squared test or Fisher\'s exact for categorical covariates, where appropriate. The *P*‐value for survival analysis was determined with log‐rank testing.

Abbreviations: CPI, checkpoint inhibitor; CTCAE, common terminology criteria for adverse events; ECOG, Eastern cooperative oncology group; IQR, interquartile range; SD, standard deviation

Statistically significant at α \< 0.05

John Wiley & Sons, Ltd

Twenty‐eight of sixty patients (47%) received ipilimumab monotherapy; 24/60 (40%) received combination CPI. Seven patients (12%) received pembrolizumab alone, one received nivolumab alone (2%), and two (3%) received alternative combinations. Median number of prior therapies was 2. Previous treatment with CPIs was uncommon (8/60, 13.3%) and no patients had had prior admissions for irAEs.

Admissions occurred a median of 73.5 days (range: 18.0‐1075.0) after first CPI dose. Presenting symptoms included diarrhea (83/88, 94%), nausea and/or vomiting (32/88, 36%), abdominal pain (37/88, 42%), melena/hematochezia (18/88, 20%), and fecal incontinence (5/88, 6%). In 49/88 admissions (55.7%), corticosteroids had been prescribed prior to admission. Admission chemistries and blood counts were typically within or near the normal range. Patients showed a mild lymphopenia (average 14.6%, 1120 cells/mL), mild anemia (average hemoglobin 12.8 g/dL), and hypoalbuminemia (average 3.6 g/dL). Erythrocyte sedimentation rate (ESR) (31.1 mm/h) and C‐reactive protein (CRP) (3.3 mg/L) were slightly elevated. One patient tested positive for *Clostridioides difficile* toxin, but the presentation was not consistent with isolated *Clostridioides difficile* colitis.

Cross‐sectional imaging was abnormal in 20/38 patients (52.6%). Diagnostic endoscopy was performed during 79/88 admissions (89.8%; 69 admissions with either an upper or lower endoscopy, 10 with both). Mucosal inflammation was found in 57/79 endoscopies (72.2%). Nearly all admitted patients received corticosteroids (57/60, 95.0%), with most instances of admission (77/88, 87.5%) involving at least 1 mg/kg prednisone or equivalent; 70/88 (79.5%) received intravenous high‐dose corticosteroid. Three of sixty (5.0%) experienced spontaneous symptom resolution without immunosuppression.

Half of our cohort (30/60, 50.0%) ultimately received second‐line immunosuppression after their treating team determined that corticosteroid treatment was insufficiently effective. In general, patients who received second‐line immunosuppression had experienced either persistent symptoms despite high‐dose corticosteroids or at least one episode of symptom recrudescence upon attempted corticosteroid taper. Most patients received infliximab (28/30, 93.3%). Emergent bowel resection occurred in two admissions (2.3%), and exploratory laparotomy in one (1.1%). Tables [1](#cam42397-tbl-0001){ref-type="table"} and [2](#cam42397-tbl-0002){ref-type="table"} display the differential associations between selected variables and second‐line immunosuppression. Ipilimumab monotherapy (*P* = 0.010), stage III disease postresection (*P* = 0.011), and the absence of gastrointestinal metastases (*P* = 0.028) were associated with second‐line immunosuppression. Patients who received second‐line immunosuppression had lower serum albumin (*P* = 0.005), lactate dehydrogenase (LDH) (*P* = 0.026), and relative lymphocyte counts (*P* = 0.027) (Table [2](#cam42397-tbl-0002){ref-type="table"}). They also tended to be younger with a higher median number of prior oncologic therapies and more weight loss (Table [S2](#cam42397-sup-0004){ref-type="supplementary-material"}).

###### 

Selected features of CPI‐related GEC presentation and initial diagnostic approach

                                                        Overall                        No use of second‐line immunosuppression   Use of second‐line immunosuppression   *P*‐value
  ----------------------------------------------------- ------------------------------ ----------------------------------------- -------------------------------------- ----------------------------------------------
  Time to presentation, days                                                                                                                                            
  Mean ± SD                                             133.1 ± 199.9                  119.8 ± 138.8                             141.8 ± 232.5                          0.616
  Median                                                73.5                           93.0                                      70.0                                   
  Presenting signs and symptoms                                                                                                                                         
  Diarrhea                                              83/88 (94.3%)                  33/35 (94.3%)                             50/53 (94.3%)                          1.000
  Nausea and/or vomiting                                32/88 (36.4%)                  10/35 (28.6%)                             22/53 (41.5%)                          0.217
  Abdominal pain                                        37/88 (42.1%)                  13/35 (37.1%)                             24/53 (45.3%)                          0.449
  Melena/hematochezia                                   18/88 (20.5%)                  6/35 (17.1%)                              12/53 (22.6%)                          0.531
  Fecal incontinence                                    5/88 (5.7%)                    3/35 (8.6%)                               2/53 (3.8%)                            0.383
  Other                                                 32/88 (36.4%)                  14/35 (40.0%)                             18/53 (34.0%)                          0.564
  Percent weight change from baseline                   −6% ± 7%                       −5% ± 5%                                  −6% ± 8%                               0.275
  Median CTCAE symptom grade (IQR)                      3 (3‐3)                        3 (2‐3)                                   3 (3‐3)                                0.198
  Median ECOG Performance Status at admission (IQR)     1 (1‐2)                        1 (1‐2)                                   1 (1‐2)                                0.897
  Laboratory results at admission: mean ± SD                                                                                                                            
  Routine chemistries                                   No significant abnormalities   No significant abnormalities              No significant abnormalities           \>0.05
  Albumin (g/dL)                                        3.6 ± 0.6                      3.8 ± 0.6                                 3.5 ± 0.6                              0.005[a](#cam42397-note-0007){ref-type="fn"}
  Lactate dehydrogenase (U/L)                           251.7 ± 28.4                   309.5 ± 273.1                             189.9 ± 69.7                           0.026[a](#cam42397-note-0007){ref-type="fn"}
  Erythrocyte sedimentation rate (ESR) (mm/h)           31.1 ± 28.4                    31.4 ± 26.8                               30.9 ± 31.2                            0.976
  C‐reactive protein (CRP) (mg/L)                       3.3 ± 2.3                      4.2 ± 2.7                                 2.9 ± 2.0                              0.294
  Complete Blood Count (CBC)                            No significant abnormalities   No significant abnormalities              No significant abnormalities           \>0.05
  Lymphocytes, relative (%)                             14.6 ± 2.1                     17.2% ± 10.0%                             12.9% ± 8.0%                           0.027[a](#cam42397-note-0007){ref-type="fn"}
  Lymphocytes, absolute (K cells/mL)                    1.12 ± 0.71                    1.31 ± 0.64                               1.11 ± 0.74                            0.193
  Corticosteroid use at admission                       49/88 (55.7%)                  17/35 (48.6%)                             32/53 (60.4%)                          0.275
  Diagnostic studies on admission                                                                                                                                       
  Radiographic signs of gastrointestinal inflammation   20/38 (52.6%)                  3/10 (30.0%)                              17/28 (60.7%)                          0.144
  Endoscopic signs of gastrointestinal inflammation     54/69 (78.2%)                  23/31 (74.2%)                             31/38 (81.6%)                          0.459

Selected presenting features of CPI‐related GEC requiring hospitalization, together with components and results of initial diagnostic approach. Inadequate bowel preparations obscuring visual examination occurred at a negligible rate. Univariate analysis displayed. The *P*‐value was calculated by ANOVA for numerical covariates and chi‐squared test or Fisher\'s exact for categorical covariates, where appropriate. Routine chemistries include the following: serum sodium (mmol/L), serum potassium (mmol/L), serum chloride (mmol/L), blood urea nitrogen (mg/dL), serum creatinine (mg/dL), lactate (mmol/L). Complete blood count includes the following: white blood cells (K cells/mL), hematocrit (%), hemoglobin (g/dL), platelets (K cells/mL). Other symptoms included fatigue, night sweats, abdominal bloating, chills, dysphagia, and hypotension. Endoscopy includes: esophagogastroduodenoscopy, flexible sigmoidoscopy, and colonoscopy.

Abbreviations: CPI, checkpoint inhibitor; CTCAE, common terminology criteria for adverse events; ECOG, Eastern cooperative oncology group; IQR, interquartile range; SD, standard deviation.

Statistically significant at α \< 0.05.

John Wiley & Sons, Ltd

The need for second‐line immunosuppression was not associated with CTCAE grade, type of CPI treatment, ECOG performance status, corticosteroid use prior to admission, or the presence/absence of radiographic or endoscopic abnormalities (Table [2](#cam42397-tbl-0002){ref-type="table"}). The presence of melena or hematochezia on admission was associated with CTCAE grade ≥2 (Table [3](#cam42397-tbl-0003){ref-type="table"}).

###### 

Selected admission‐specific variables by CTCAE grade

                                                                    CTCAE 1        CTCAE 2         CTCAE 3         CTCAE 4        *P*‐value
  ----------------------------------------------------------------- -------------- --------------- --------------- -------------- ----------------------------------------------
  Number of cases                                                   1              13              70              3              0.253
  Clinical features                                                                                                               
  Diarrhea                                                          1/1 (100.0%)   12/13 (92.3%)   67/70 (95.7%)   2/3 (66.7%)    0.160
  Nausea/vomiting                                                   0/1 (0.0%)     5/13 (38.5%)    26/70 (37.1%)   1/3 (33.3%)    1.000
  Abdominal pain                                                    1/1 (100.0%)   5/13 (38.5%)    30/70 (42.9%)   2/3 (66.7%)    0.889
  Melena/hematochezia                                               1/1 (100.0%)   0/13 (0.0%)     15/70 (21.4%)   2/3 (66.7%)    0.042[a](#cam42397-note-0010){ref-type="fn"}
  Fecal incontinence                                                1/1 (100.0%)   0/13 (0.0%)     5/70 (7.1%)     0/3 (0.0%)     1.000
  Other                                                             0/1 (100.0%)   7/13 (53.9%)    24/70 (34.3%)   1/3 (33.3%)    0.525
  Endoscopy abnormalities                                           N/A            7/10 (70.0%)    44/56 (78.6%)   2/2 (100.0%)   0.808
  Time to admission in days                                                                                                       
  Mean ± SD                                                         59 ± N/A       133.4 ± 198.2   137.8 ± 207.7   85 ± 16.8      0.954
  Median                                                            59             74              76.5            91             
  Length of stay in days per admission                                                                                            
  Mean ± SD                                                         6 ± N/A        5.5 ± 4.3       5.5 ± 4.0       12.7 ± 2.9     0.033[a](#cam42397-note-0010){ref-type="fn"}
  Median                                                            6              4               4               11             
  GEC symptom return to grade 1 or baseline after first admission                                                                 
  At 1 mo postdischarge                                             1/1 (100.0%)   6/7 (85.7%)     42/46 (91.3%)   0/1 (0.0%)     0.098
  At 3 mo postdischarge                                             0/0 (N/A)      5/5 (100.0%)    40/41 (97.6%)   2/2 (100.0%)   1.000

Selected variables regarding patients with CPI‐related GEC, stratified by CTCAE grade upon presentation. Univariate analysis displayed. The *P*‐value was calculated by ANOVA for numerical covariates and chi‐squared test or Fisher\'s exact for categorical covariates, where appropriate.

Abbreviations: CPI, checkpoint inhibitor; CTCAE, Common Terminology Criteria for Adverse Events; GEC, gastroenterocolitis; NE, not estimable; SD, standard deviation.

Statistically significant at α \< 0.05.

John Wiley & Sons, Ltd

3.2. Endpoints {#cam42397-sec-0014}
--------------

### 3.2.1. Primary endpoint assessment {#cam42397-sec-0015}

We characterized oncologic outcomes and associations with second‐line immunosuppression (Table [4](#cam42397-tbl-0004){ref-type="table"}, Figure [2](#cam42397-fig-0002){ref-type="fig"}). Overall mean PFS and OS were 23.8 and 36.1 months, respectively (medians 14.5 and 54.6 months). Mean PFS and OS for patients without second‐line immunosuppression were 12.2 and 24.2 months (medians 10.8 and 35.6 months). Mean PFS and OS for those who received second‐line immunosuppression were 26.4 and 39.4 months (medians 30.6 and 54.6 months). No significant differences in second‐line immunosuppression were observed in PFS (*P* = 0.367 log‐rank, 0.174 Wilcoxon) or OS (*P* = 0.400 log‐rank, 0.298 Wilcoxon).

###### 

Characteristics of hospital and postdischarge course

                                                                    Overall          No use of second‐line immunosuppression   Use of second‐line immunosuppression   *P*‐value
  ----------------------------------------------------------------- ---------------- ----------------------------------------- -------------------------------------- -----------
  Length of stay in days per admission                                                                                                                                
  Mean ± SD                                                         5.8 ± 4.2        5.2 ± 3.7                                 6.3 ± 4.5                              0.226
  Median                                                            4.5              4.0                                       5.0                                    
  Readmissions for recrudescence                                                                                                                                      
  Number of patients requiring \>1 readmission                      20/60 (33.3%)    5/30 (16.7%)                              15/30 (50.0%)                          0.091
  Number of patients requiring ≥1 readmission                       6/60 (10.0%)     0/30 (0.0%)                               6/30 (20.0%)                           0.055
  GEC symptom return to grade 1 or baseline after first admission                                                                                                     
  At 1 mo postdischarge                                             49/56 (87.5%)    24/28 (85.7%)                             25/28 (89.3%)                          0.669
  At 3 mo postdischarge                                             50/51 (98.0%)    22/23 (95.7%)                             28/28 (100.0%)                         0.451
  Progression‐free Survival                                                                                                                                           
  Mean ± SE                                                         23.8 ± 2.5       12.2 ± 1.6                                26.4 ± 3.6                             0.367
  Median (CI)                                                       14.5 (6.6‐NE)    10.8 (4.8‐NE)                             30.6 (6.5‐NE)                          
  Overall survival                                                                                                                                                    
  Mean ± SE                                                         36.1 ± 2.9       24.2 ± 2.6                                39.4 ± 4.2                             0.400
  Median (CI)                                                       54.6 (30.8‐NE)   35.6 (12.2‐NE)                            54.6 (13.7‐NE)                         

Characteristics of later hospital course and postdischarge course as primary and secondary endpoints of the study. GEC symptoms were inquired after at standard oncologic follow‐up visits. Of note, the total number of patients decreased over time, yielding decreasing denominators in "GEC symptom resolution after first admission." Univariate analysis displayed. The *P*‐value was calculated by ANOVA for numerical covariates and chi‐squared test or Fisher\'s exact for categorical covariates, where appropriate.

Abbreviations: GEC, gastroenterocolitis; NE, not estimable; SD, standard deviation; SE, standard error.

John Wiley & Sons, Ltd

![Kaplan‐Meier survival graphs depicting oncologic outcomes. A, PFS, overall population. B, OS, overall population. C, PFS, stratified by use of second‐line immunosuppression. D, OS, stratified by use of second‐line immunosuppression. CI, confidence interval; OS, overall survival; PFS, progression‐free survival](CAM4-8-4986-g002){#cam42397-fig-0002}

We also examined oncologic outcomes with respect to the timing of GEC and subsequent corticosteroid exposure in patients with stage IV melanoma who received at least two cycles of ipilimumab, divided at median time to corticosteroid administration: "early exposure," defined as receiving corticosteroids for GEC within 64 days after CPI administration; and "late exposure," defined as receiving corticosteroids for GEC at least 64 days after CPI administration. Decreased PFS was significantly associated with early exposure (*P* = 0.045 log‐rank, 0.025 Wilcoxon) with no statistically significant effect on OS (Figure [3](#cam42397-fig-0003){ref-type="fig"}B). Cox proportional hazard modeling of the effect of corticosteroid administration timing on PFS, controlling for age at admission and patient sex, showed a hazard ratio of 2.26 (95% confidence interval: 1.00‐5.11, *P* = 0.051; Table S3). Similar analyses for other types of corticosteroid exposures revealed significant differences (Figure [S1](#cam42397-sup-0001){ref-type="supplementary-material"}). The same analyses for the time interval between symptom onset and corticosteroid exposures revealed no significant differences in PFS or OS. By the same token, "early" admission was associated with poorer PFS at borderline significance (*P* = 0.133 log‐rank, 0.046 Wilcoxon) but showed no significant difference in OS. Timings of analyzed corticosteroid exposures were significantly collinear with time to admission (Figure [S2](#cam42397-sup-0002){ref-type="supplementary-material"}).

![Kaplan‐Meier survival curves for oncologic outcomes in patients with stage IV melanoma who received at least two cycles of ipilimumab, stratified by GEC/corticosteroid exposure. Time threshold: 64 days. One patient had unclear corticosteroid dosing timing and was therefore not included in this analysis. \*\*Denotes significance at α \< 0.05. A, PFS, stratified by time from initial ICI administration to earliest GEC/corticosteroid exposure at any dose. B, OS, stratified by time from initial ICI administration to earliest GEC/corticosteroid exposure at any dose. GEC, gastroenterocolitis; OS, overall survival; PFS, progression‐free survival](CAM4-8-4986-g003){#cam42397-fig-0003}

### 3.2.2. Secondary endpoint assessment {#cam42397-sec-0016}

Average LOS was 5.8 ± 4.2 days; median LOS was 4.5 days. Readmission for GEC recrudescence was 33.3% (20/60); 30.0% of the cohort (18/60) were readmitted within 30 days. About 10.0% (6/60) required multiple readmissions. Maximum number of readmissions was three. GEC resolution rate was 87.5% (49/56) at 1 month postdischarge and 98.0% (50/51) at 3 months postdischarge (Figure [4](#cam42397-fig-0004){ref-type="fig"}); the same pattern was observed regardless of second‐line immunosuppression use. No differences in LOS or rate of readmission for GEC recrudescence between patients who received second‐line immunosuppression and those who did not were observed. CTCAE grade was overall not significantly associated with short‐term outcomes, but grade 4 severity was associated with LOS approximately 1 week longer than that of other grades (12.7 days vs 5.5 days, *P* = 0.033) and grade 2 cases tended to worsen within 1 month of discharge (Table [3](#cam42397-tbl-0003){ref-type="table"}). The small number of grade 4 cases precluded meaningful long‐term survival analysis. Patients who received second‐line immunosuppression tended to be readmitted more often (*P* = 0.091) and to require multiple readmissions (*P* = 0.055).

![Proportions of patients with GEC symptom resolution to grade 1 or baseline, stratified by secondline immunosuppression. *P* \> 0.05 by ANOVA. GEC, gastroenterocolitis](CAM4-8-4986-g004){#cam42397-fig-0004}

Early IV steroid exposure was associated with lower likelihood of readmission for recrudescence (*P* = 0.019). Any early steroid exposure showed lower likelihood of readmission for recrudescence but did not reach significance (*P* = 0.060). No differences were observed in LOS.

3.3. Additional analysis {#cam42397-sec-0017}
------------------------

Melanoma and irAE treatment strategies changed over our study period. We accordingly characterized patterns of second‐line immunosuppression use and time from admission to infliximab administration over 2011‐2017 in patients receiving ipilimumab‐containing regimens. Infliximab use did not vary significantly over the 6 years studied (Table [5](#cam42397-tbl-0005){ref-type="table"}). Likewise, no significant variation was noted in time to infliximab administration (Table [6](#cam42397-tbl-0006){ref-type="table"}). Mean time from initial admission to infliximab exposure intervals ranged from 11.3 days in January 2016 to December 2017 to 51.2 days in January 2014 to December 2015; median interval range was small, between 19 days in January 2016 to December 2017 and 20.5 days prior to January 2014 (*P* = 0.188).

###### 

Univariate Analysis of Ipilimumab Administration by Use of Second‐Line Immunosuppression over Study Timespan

                                                                      Use of second‐line immunosuppression (%)   *P*‐value
  ------------------------------------------------------------------- ------------------------------------------ -----------
  Number of patients with anti‐CTLA‐4 containing regimen, 2011‐2017   29/52 (55.8%)                              0.694
  Prior to January 2013                                               13/18 (72.2%)                              0.564
  January 2014 to December 2015                                       7/23 (30.4%)                               
  January 2016 to December 2017                                       9/11 (81.8%)                               

Univariate analysis of change in selected variables over study\'s timespan. Analysis of ipilimumab use over time. Statistically significant differences not observed.

The *P*‐value was calculated by ANOVA for numerical covariates and chi‐squared test or Fisher\'s exact for categorical covariates, where appropriate.

CTLA‐4, cytotoxic T‐lymphocyte antigen‐4

Statistically significant at α \< 0.05.

John Wiley & Sons, Ltd

###### 

Univariate analysis of time from first admission to TNFαi administration over study timespan

                                  Time to TNFαi (days)
  ------------------------------- ----------------------
  Prior to January 2014           0.188
  Mean ± SD                       18.1 ± 12.2
  Median                          20.5
  January 2014 to December 2015   
  Mean ± SD                       51.2 ± 68.5
  Median                          19.5
  January 2016 to December 2017   
  Mean ± SD                       11.3 ± 46.9
  Median                          19

Univariate analysis of change in selected variables over study\'s timespan. Analysis of change in time interval from first admission to TNFαi administration, as surrogate for need for second‐line immunosuppression, over study\'s timespan. No statistically significant differences seen, including in results by individual year (not shown). The *P*‐value was calculated by ANOVA for numerical covariates and chi‐squared test or Fisher\'s exact for categorical covariates, where appropriate.

Abbreviations: SD, standard deviation; TNFαi: tumor necrosis factor alpha inhibitor.

Statistically significant at α \< 0.05.

John Wiley & Sons, Ltd

4. DISCUSSION {#cam42397-sec-0018}
=============

In this retrospective, single‐center study, we describe the typical disease course of CPI‐related GEC requiring hospitalization in patients with advanced melanoma, including postdischarge outcomes, and we identify factors associated with second‐line immunosuppression use for symptom control. Survival analysis suggests that while second‐line immunosuppression is not associated with worse PFS or OS, increased time from initial CPI to corticosteroid administration is significantly associated with increased PFS and is collinear with time to admission.

CPI‐related GEC is a common irAE accompanied by significant morbidity and mortality. One‐quarter of patients receiving anti‐CTLA‐4 therapy develop low‐grade GEC, while 11% experience severe GEC; 10%‐20% of patients exposed to anti‐PD‐1/PD‐L1 develop a low‐grade GEC, while 2% develop high‐grade symptoms.[1](#cam42397-bib-0001){ref-type="ref"}, [8](#cam42397-bib-0008){ref-type="ref"}, [9](#cam42397-bib-0009){ref-type="ref"}, [10](#cam42397-bib-0010){ref-type="ref"}, [13](#cam42397-bib-0013){ref-type="ref"}, [17](#cam42397-bib-0017){ref-type="ref"} As expected, combination therapy seems to have at least an additive, if not synergistic, effect on toxicity.[9](#cam42397-bib-0009){ref-type="ref"}, [10](#cam42397-bib-0010){ref-type="ref"} Empiric evidence in CPI‐related GEC suggests that gastrointestinal immune homeostasis is often significantly disrupted in the setting of CPI therapy,[1](#cam42397-bib-0001){ref-type="ref"} but pathogenesis is not fully understood. In general, the self‐targeting seen in irAEs is felt to be the result of an underlying predisposition to autoimmunity, with or without shared tumor‐tissue antigenicity, triggered by disinhibited T‐lymphocytes.[12](#cam42397-bib-0012){ref-type="ref"}, [21](#cam42397-bib-0021){ref-type="ref"} There seem to be multiple mechanisms through which such cells act to produce symptoms of autoimmune disease: for example, direct tissue infiltration is seen in vitiligo and myocarditis[21](#cam42397-bib-0021){ref-type="ref"}, [22](#cam42397-bib-0022){ref-type="ref"}; autoantibody generation is seen in myasthenia gravis and meningoencephalitis[23](#cam42397-bib-0023){ref-type="ref"}, [24](#cam42397-bib-0024){ref-type="ref"}; and toxicities mediated by inflammatory cytokines are seen in PD‐1 inhibitor‐induced cytokine release syndrome.[25](#cam42397-bib-0025){ref-type="ref"}

From previously published data, CPI‐related GEC was typically present with diarrhea, abdominal pain, and evidence of gastrointestinal tract ulceration, similar to inflammatory bowel disease.[1](#cam42397-bib-0001){ref-type="ref"}, [12](#cam42397-bib-0012){ref-type="ref"} Symptom onset ranges from 6 weeks to several months after initial CPI administration. Inflammation most often affects the colon and can be concomitantly seen in stomach or small intestine; however, isolated gastritis or enteritis can also occur.[26](#cam42397-bib-0026){ref-type="ref"}, [27](#cam42397-bib-0027){ref-type="ref"} Diagnostic approaches include radiography and endoscopy with further histopathologic examination. Upon endoscopy, enteritis and gastritis are typically characterized by significant ulceration.[1](#cam42397-bib-0001){ref-type="ref"}, [12](#cam42397-bib-0012){ref-type="ref"}, [15](#cam42397-bib-0015){ref-type="ref"} There are two primary patterns of colitis reported: similar significant ulcerations or normal mucosa with microscopic damage.[1](#cam42397-bib-0001){ref-type="ref"} Management of CPI‐related GEC relies on high‐dose corticosteroids with escalation to infliximab, though alternative second‐line therapies are emerging.[7](#cam42397-bib-0007){ref-type="ref"}, [28](#cam42397-bib-0028){ref-type="ref"} The particular steroid administered does not seem to impact clinical course.[7](#cam42397-bib-0007){ref-type="ref"}, [29](#cam42397-bib-0029){ref-type="ref"} The prognostic implications of developing CPI‐related GEC on oncologic outcomes are uncertain; other irAEs have been associated with improved survival, but few data link GEC and antitumor effect.[30](#cam42397-bib-0030){ref-type="ref"}, [31](#cam42397-bib-0031){ref-type="ref"}

From our analysis, we conclude that patients with severe CPI‐related GEC generally develop symptoms approximately 9 weeks post‐initial CPI, 1 week more than the median time to presentation for any‐severe CPI‐related GEC reported previously,[20](#cam42397-bib-0020){ref-type="ref"} and are admitted at a median of 10 weeks from initial CPI administration. Common clinical features include diarrhea, abdominal pain, and nausea and vomiting. A smaller proportion also manifested with melena or hematochezia. Compared with the reported presentation of nonsevere CPI‐related GEC, the severe form of the condition is associated with a higher incidence of melena and hematochezia.[15](#cam42397-bib-0015){ref-type="ref"}, [32](#cam42397-bib-0032){ref-type="ref"} Intriguingly, we report a lower prevalence of abdominal pain.[15](#cam42397-bib-0015){ref-type="ref"}, [32](#cam42397-bib-0032){ref-type="ref"}

Diagnostic workup in the overall cohort was notable for the difference between radiography and endoscopy in revealing inflammation. The substantially lower rate at which imaging was performed may reflect adaptation of clinical practice to the fact that radiography was often unremarkable, whereas endoscopy was abnormal in most of the cases in which it was performed. Several recent investigations have suggested serologic markers for severe CPI‐related GEC development.[33](#cam42397-bib-0033){ref-type="ref"}, [34](#cam42397-bib-0034){ref-type="ref"}, [35](#cam42397-bib-0035){ref-type="ref"} In particular, high‐risk endoscopic findings including significant ulceration have been associated with the need for second‐line immunosuppression.[36](#cam42397-bib-0036){ref-type="ref"} In our cohort, second‐line immunosuppression was administered at a 50.0% frequency, a rate higher than the 22.5% rate in previous reports, likely reflecting the overall higher acuity of this cohort as admission to a tertiary care hospital was a requirement for study inclusion.[32](#cam42397-bib-0032){ref-type="ref"} Second‐line immunosuppression was initiated in consultation with an expert in GI‐related irAEs. The decision to pursue such a consultation occurred at the primary oncologist\'s discretion. All patients who received second‐line immunosuppression exhibited at least 24 hours of persistent severe GEC despite high‐dose corticosteroids or had demonstrated significant symptom recrudescence, though no specific criteria were used to make this treatment decision in our cohort. Our rate of surgical therapeutic intervention (3.4%) was comparable to that of prior investigations (6%), underscoring the importance of careful monitoring of patients with severe CPI‐related GEC.[32](#cam42397-bib-0032){ref-type="ref"}

Regardless of second‐line immunosuppression, however, patients with severe CPI‐related GEC are high short‐term utilizers of healthcare services. The median LOS for severe CPI‐related GEC was comparable to that of the general cancer patient admission at a comparable institution.[37](#cam42397-bib-0037){ref-type="ref"} Rate of readmission for recrudescence was 33.3%, which is lower than reported overall rates of cancer patient readmission (43%).[37](#cam42397-bib-0037){ref-type="ref"} Our 30‐day rate of readmission for recrudescence (30.0%), however, was substantially higher than reported values for 30‐day unplanned readmission rates in cancer patients (14.9%).[38](#cam42397-bib-0038){ref-type="ref"} Nevertheless, if patients were not readmitted within the first 3 months postdischarge, symptoms almost invariably resolved (98.0%) during the same timeframe. Additionally, early IV steroids resulted in a lower readmission rate. Average PFS was comparable to published estimates for standard CPI regimens in advanced melanoma.[9](#cam42397-bib-0009){ref-type="ref"}, [39](#cam42397-bib-0039){ref-type="ref"}

In our study, more severe relative lymphopenia, lower serum albumin, and lower LDH are significantly correlated with higher chance of second‐line immunosuppression use. The absolute differences are small; however, they may indicate the underlying mechanisms of disease. Hypoalbuminemia may result from enteric ulcerations that are associated with more severe GEC.[34](#cam42397-bib-0034){ref-type="ref"}, [35](#cam42397-bib-0035){ref-type="ref"}, [36](#cam42397-bib-0036){ref-type="ref"} The difference in relative lymphopenia we observed, without significant difference in absolute lymphopenia, may indicate increased neutrophilic production, driven perhaps in part by elevated interleukin‐17 levels[40](#cam42397-bib-0040){ref-type="ref"} but more likely by multiple cytokines generated in response to gastrointestinal mucosal compromise and subsequent immune activation by microbial products. Lower LDH may suggest that CPI‐related GEC which requires hospitalization and second‐line immunosuppression is actually a positive prognostic factor for oncologic response.[41](#cam42397-bib-0041){ref-type="ref"} The significant differences in second‐line immunosuppression for age, tumor stage, and the absence of non‐hepatic gastrointestinal tract metastases are most likely due to a heterogeneous population and dose‐dependent ipilimumab toxicity: during 2011‐2017, a small number of patients with high‐risk nonmetastatic melanoma were treated with adjuvant ipilimumab at an increased dose. High‐dose ipilimumab used as adjuvant therapy has been shown in stage III melanoma to prolong survival but also to increase the risk of irAE.[42](#cam42397-bib-0042){ref-type="ref"}

We detected no significant difference in second‐line immunosuppression use or rate of readmission for CTCAE grade. Such findings demonstrate that substantial heterogeneity in severe CPI‐related GEC is not adequately captured by CTCAE alone: a more nuanced classification system with stronger correlation to second‐line immunosuppression use and readmission is needed. CTCAE grade 4 cases do present more frequently with melena or hematochezia, as might be expected if severity of mucosal ulceration is correlated with severity of disease. CTCAE grade 4 cases also stay approximately 1 week more in the hospital; however, this is most likely due to a distribution of CTCAE grades skewed toward 3.

Our survival analyses indicate that second‐line immunosuppression in severe CPI‐related GEC does not negatively impact oncologic outcomes and does not affect LOS or readmission frequency. Intriguingly, our findings suggest that, in a subset of patients, decreased time from CPI administration to GEC development and subsequent corticosteroids at any dose is linked to poorer PFS. In the same group of patients, decreased time from CPI administration to admission tended toward poorer outcomes as well but did not reach significance by log‐rank testing. The two variables were also shown to be highly colinear. Significant differences were noted at the 64‐day threshold; other exposure parameters showed borderline significance (Figure [S1](#cam42397-sup-0001){ref-type="supplementary-material"}).

Patients who were admitted later for CPI‐related GEC and who thus received corticosteroids later may have benefited from receiving more immunotherapy, potentially accounting for the observed difference in PFS. However, the association between early corticosteroid administration and decreased PFS is also compatible with a model of cancer immunotherapy‐related autoimmune disease in which corticosteroids impact the antitumor response. Several prior retrospective studies have not found that steroids reduce antitumor immune activity.[43](#cam42397-bib-0043){ref-type="ref"} On the other hand, prior in vitro and animal experiments have shown that glucocorticoids block antibody‐dependent tumor cell destruction[44](#cam42397-bib-0044){ref-type="ref"}; may abrogate interleukin‐1α‐mediated antitumor activity[45](#cam42397-bib-0045){ref-type="ref"}; and upregulate CTLA‐4 in animal models of intracranial gliomas responsive to CTLA‐4 inhibition.[46](#cam42397-bib-0046){ref-type="ref"} A recent study concluded in addition that infliximab, in contrast to corticosteroids, had little to no negative impact on tumor‐infiltrating lymphocyte function.[47](#cam42397-bib-0047){ref-type="ref"}

Whether or not such effects induced by corticosteroids are clinically important and remain unclear; however, a significant association between corticosteroid administration prior to immunotherapy initiation and poorer oncologic outcomes in patients with nonsmall‐cell lung cancer has been reported in a retrospective cohort study,[48](#cam42397-bib-0048){ref-type="ref"} and a recent retrospective study of ipilimumab‐induced hypophysitis in patients with advanced melanoma suggested that higher corticosteroid doses resulted in reduced OS.[49](#cam42397-bib-0049){ref-type="ref"} Our findings additionally suggest that corticosteroid timing may play a role in immunotherapy response, but further prospective study will be required to determine whether corticosteroids have a direct impact on antitumor responses. While early corticosteroid exposure may, to some extent, limit antitumor responses, high‐dose corticosteroids in acute irAEs nevertheless clearly constitute lifesaving first‐line treatment for many patients.[7](#cam42397-bib-0007){ref-type="ref"}

As these were univariate survival analyses performed in a subset of patients, our findings may be confounded by multiple factors, including codependence. Our cohort\'s heterogeneous CPI exposure is another potential confounding variable. Other limitations include a retrospective study design, which does not allow for causality inference and is inherently confounded by survival bias. Small sample size limited our power to make statistical observations. Our 6‐year study period encompassed substantial changes in standard‐of‐care therapy for melanoma.[50](#cam42397-bib-0050){ref-type="ref"}, [51](#cam42397-bib-0051){ref-type="ref"} Of note, though many patients received ipilimumab monotherapy and few patients received PD‐1‐targeted monotherapies, combination CPI regimens are well‐represented, allowing for limited generalizability and indicating a need for further study.

5. CONCLUSIONS {#cam42397-sec-0019}
==============

Typical CPI‐related GEC requiring hospitalization manifests within 3 months of initial CPI with a distinct constellation of clinical features. Diagnostic workup shows multiple abnormalities, several of which may be associated with second‐line immunosuppression use. Overall, 50% of patients receive second‐line immunosuppression. Readmission for recrudescence is frequent. If patients are not readmitted for symptom recrudescence, however, their GEC will most likely substantially improve within 3 months postdischarge. Second‐line immunosuppression has no detrimental effect on oncologic outcomes, but corticosteroid timing may.

Further studies in CPI‐related GEC requiring hospitalization are needed to: (a) add nuance to the "classic" clinical description above; (b) construct a more granular grading system that accounts for inpatient disease severity; (c) corroborate our survival analysis findings; and (d) prospectively parse the survival impact of time from initial CPI exposure to corticosteroid administration apart from that of time on immunotherapy.
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